- Home
- BAH vs BMRN Comparison
BAH vs BMRN Comparison
Compare BAH & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | BMRN |
|---|---|---|
| Founded | 1914 | 1996 |
| Country | United States | United States |
| Employees | 35800 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.5B |
| IPO Year | 2010 | 1999 |
Fundamental Metrics
Financial Performance| Metric | BAH | BMRN |
|---|---|---|
| Price | $81.43 | $54.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 18 |
| Target Price | ★ $98.33 | $88.22 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-22-2026 | 04-24-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 57.95 | N/A |
| EPS | ★ 5.22 | 1.80 |
| Revenue | ★ $11,980,000,000.00 | $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | $2.14 | $12.23 |
| P/E Ratio | ★ $15.84 | $30.04 |
| Revenue Growth | 12.36 | ★ 17.62 |
| 52 Week Low | $73.93 | $50.76 |
| 52 Week High | $130.91 | $66.28 |
Technical Indicators
Market Signals| Indicator | BAH | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 42.51 |
| Support Level | $75.89 | $53.71 |
| Resistance Level | $81.92 | $56.21 |
| Average True Range (ATR) | 2.73 | 1.38 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 49.49 | 19.65 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.